Status:
COMPLETED
Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
Lead Sponsor:
University Hospital, Tours
Conditions:
Kidney Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood co...
Detailed Description
Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in terms of efficacy ...
Eligibility Criteria
Inclusion
- Patient with squamous or non squamous non small cell lung cancer stage IV or patient with renal cell carcinoma stage IV
- Patient receiving nivolumab or who will receive nivolumab
- Age ⩾ 18 years old
- OMS stage ≤ 2
- Evaluable disease
Exclusion
- Active brain metastasis not treated before by surgery or radiotherapy
- Autoimmune disease
- Patient having objected to the processing of his data
Key Trial Info
Start Date :
January 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2018
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03433534
Start Date
January 29 2018
End Date
December 21 2018
Last Update
November 12 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical oncology department, University Hospital, Tours
Tours, France, 37044
2
Pneumology department, University Hospital, Tours
Tours, France, 37044